3.8 Article

Distinct Phenotypic Clusters of Glioblastoma Growth and Response Kinetics Predict Survival

期刊

JCO CLINICAL CANCER INFORMATICS
卷 2, 期 -, 页码 -

出版社

LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1200/CCI.17.00080

关键词

-

类别

资金

  1. James S. McDonnell Foundation
  2. Ivy Foundation
  3. Mayo Clinic
  4. James D. Murray Endowed Chair
  5. National Institutes of Health [R01NS060752, R01CA164371, U54CA210180, U54CA143970, U54CA193489, U01CA220378]

向作者/读者索取更多资源

Purpose Despite the intra- and intertumoral heterogeneity seen in glioblastoma multiforme (GBM), there is little definitive data on the underlying cause of the differences in patient survivals. Serial imaging assessment of tumor growth allows quantification of tumor growth kinetics (TGK) measured in terms of changes in the velocity of radial expansion seen on imaging. Because a systematic study of this entire TGK phenotype-growth before treatment and during each treatment to recurrence -has never been coordinately studied in GBMs, we sought to identify whether patients cluster into discrete groups on the basis of their TGK. Patients and Methods From our multi-institutional database, we identified 48 patients who underwent maximally safe resection followed by radiotherapy with imaging follow-up through the time of recurrence. The patients were then clustered into two groups through a k-means algorithm taking as input only the TGK before and during treatment. Results There was a significant survival difference between the clusters (P= .003). Paradoxically, patients among the long-lived cluster had significantly larger tumors at diagnosis (P = .027) and faster growth before treatment (P = .003) but demonstrated a better response to adjuvant chemotherapy (P = .048). A predictive model was built to identify which cluster patients would likely fall into on the basis of information that would be available to clinicians immediately after radiotherapy (accuracy, 90.3%). Conclusion Dichotomizing the heterogeneity of GBMs into two populations-one faster growing yet more responsive with increased survival and one slower growing yet less responsive with shorter survival-suggests that many patients who receive standard-of-care treatments may get better benefit from select alternative treatments. (C) 2018 by American Society of Clinical Oncology

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

3.8
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据